Morepen Starts ₹825 Cr CDMO Supplies, Completes ₹50 Cr First Dispatch

Morepen Laboratories Limited has commenced commercial supplies under its significant ₹825 crore CDMO (Contract Development and Manufacturing Organization) mandate. The company announced the completion of its first dispatch, valued at approximately ₹50 crore, in Q1FY2026-27. This marks a crucial transition from the validation phase to commercial execution. Morepen anticipates further scaling up operations, with an estimated ₹225 crore in additional supplies expected in Q2FY2026-27. To support this growth, the company is expanding its manufacturing infrastructure, aiming for 600 KL reactor capacity by the end of Q2 and further expansion to 800 KL and 1,000 KL in subsequent phases. This move reinforces Morepen's strategy to build a robust CDMO platform and secure long-term global manufacturing partnerships.